Cancer therapy directed by comprehensive genomic profiling: A single center study

Cancer Research

Volumn 76, Issue 13, 2016, Pages 3690-3701

  Wheler, Jennifer J ^a   Janku, Filip ^a   Naing, Aung ^a   Li, Yali ^b   Stephen, Bettzy ^a   Zinner, Ralph ^a   Subbiah, Vivek ^a   Fu, Siqing ^a   Karp, Daniel ^a   Falchook, Gerald S ^c   Tsimberidou, Apostolia M ^a   Piha Paul, Sarina ^a   Anderson, Roosevelt ^a   Ke, Danxia ^a   Miller, Vincent ^b   Yelensky, Roman ^b   Lee, J Jack ^a   Hong, David S ^a   Kurzrock, Razelle ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOUNDATION MEDICINE   (United States)

^c HealthOne   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CANCER TISSUE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DEATH; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; HOSPICE CARE; HUMAN; HUMAN TISSUE; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; NEXT GENERATION SEQUENCING; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SARCOMA; TIME TO TREATMENT FAILURE; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEOPLASMS; PRECISION MEDICINE; PROGNOSIS; PROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SURVIVAL RATE; YOUNG ADULT;

EID: 84977530459     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3043     Document Type: Article

References (55)

1. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005;352:895-904.
2. Kurzrock R, Benjamin RS. Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med 2005;352:930-2.
3. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012;18: 6373-83.
4. Khozin S, Blumenthal GM, Zhang L, Tang S, Brower M, Fox E, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res 2015;21: 2436-9.
5. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 2015;25:71-7.
6. Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, et al. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol 2013;24:2158-65.
7. Chabner BA. Approval after phase I: ceritinib runs the three-minute mile. Oncologist 2014;19:577-8.
8. Wheler J, Lee JJ, Kurzrock R. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res 2014;74:7181-4.
9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
10. Aguirre D, Boya P, Bellet D, Faivre S, Troalen F, Benard J, et al. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 2004;9: 797-805.
11. Atipairin A, Canyuk B, Ratanaphan A. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs. Breast Cancer Res Treat 2011;126:203-9.
12. Awada A, Dirix L, Sanchez LM, Xu B, Luu T, Dieras V, et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ERBB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol 2013;24:109-16.
13. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28:375-9.
14. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
15. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
16. Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]- 2-pyrimidinyl]amino]-2-methyl-b enzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008;51:4632-40.
17. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014;6:377-87.
18. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011;10:558-65.
19. Kelly K, Mazieres J, Leighl N, Barlesi F, Zalcman G, Gordon M, et al. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): a phase I/Ib trial. J Clin Oncol 31, 2013(suppl; abstr 8027).
20. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6:2012-21.
21. Lai LP, Lilley BN, Sanes JR, McMahon AP. Lkb1/Stk11 regulation of mTOR signaling controls the transition of chondrocyte fates and suppresses skeletal tumor formation. Proc Natl Acad Sci U S A 2013;110:19450-5.
22. Mao JH, Kim IJ, Wu D, Climent J, Kang HC, Del Rosario R, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008;321:1499-502.
23. Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med 2014;46: 372-83.
24. Natsume H, Shinmura K, Tao H, Igarashi H, Suzuki M, Nagura K, et al. The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. J Transl Med 2012;10:97.
25. Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won HL, Liu CL, et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res 2014;74:2340-50.
26. Piha-Paul SA, Hong DS, Kurzrock R. Response of lymphangioleiomyomatosis to amammalian target of rapamycin inhibitor (temsirolimus) -based treatment. J Clin Oncol 2011;29:e333-5.
27. Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 2006;98:756-62.
28. Romer MU, Jensen NF, Nielsen SL, Muller S, Nielsen KV, Nielsen HJ, et al. TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity. Scand J Gastroenterol 2012;47: 68-79.
29. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, et al. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 2013;4:705-14.
30. Sak MM, Szymanska M, Bertelsen V, Hasmann M, Madshus IH, Stang E. Pertuzumab counteracts the inhibitory effect of ERBB2 on degradation of ERBB3. Carcinogenesis 2013;34:2031-8.
31. Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget 2014;5:5295-303.
32. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-81.
33. Schwaederle M, Lazar V, Validire P, Hansson J, Lacroix L, Soria JC, et al. VEGF-A expression correlates with TP53 mutations in non-small cell lung cancer: implications for antiangiogenesis therapy. Cancer Res 2015;75: 1187-90.
34. Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res 2013;19: 5320-28.
35. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-42.
36. Sonpavde G, Willey CD, Sudarshan S. Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. Expert Opin Investig Drugs 2014;23:305-15.
37. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-ofconcept trial. Lancet 2010;376:235-44.
38. Vandyke K, Fitter S, Zannettino AC. The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer J 2011;1:e2.
39. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012;120: 1202-9.
40. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
41. Ward JE, Stadler WM. Pazopanib in renal cell carcinoma. Clin Cancer Res 2010;16:5923-7.
42. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, et al. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res 2012; 18:2922-9.
43. Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, et al. Combining erlotinib and cetuximab is associated with activity in patients with non small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther 2013;12:2167-75.
44. Williams JA, Guicherit CM, Zaharian B, Xu Y, Chai L, Wichterle H, et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions (vol 100, pg 4616, 2003). Proc Natl Acad Sci U S A 2003;100:8607-07.
45. Zhou CC, Wu YL, Chen GY, Feng JF, Liu XQ, Wang CL, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG- 0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
46. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 2009;27:2692-96.
47. Cox DR. Regression models and life-tables. J Roy Stat Soc Series B Stat Methodol 1972;34:187-220.
48. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31: 1023-31.
49. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu SQ, Hong DS, et al. Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer 2012;118:1422-28.
50. Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, et al. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget 2015;6:14139-52.
51. Von Hoff DD, Stephenson JJ, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010;28:4877-82.
52. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, et al. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget 2014;5:2349-54.
53. Le Tourneau C, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015;16:1324-34.
54. Myers AP, Cantley LC. Targeting a common collaborator in cancer development. Sci Transl Med 2010:2:48ps45.
55. Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, et al. On the road to precision cancer medicine: analysis of genomic biomarker actionability in 439 patients. Mol Cancer Ther 2015;14:1488-94.